Browsing Tag
Drug discovery
45 posts
Recursion Pharmaceuticals (NASDAQ: RXRX) stock rises after 20% workforce cut and pipeline reset
Recursion Pharmaceuticals (NASDAQ: RXRX) cuts 20% of workforce to extend runway and narrow pipeline focus—read what this means for its AI drug discovery strategy.
Atai Life Sciences acquires exclusive rights to Psilera’s DMT patent portfolio
Atai Life Sciences has taken a strategic step in expanding its position in psychedelic medicine by securing exclusive…
Wockhardt’s Zaynich achieves record-breaking 96.8% clinical cure rate in cUTI Phase III trial
Wockhardt Limited has announced a major breakthrough in the treatment of complicated urinary tract infections (cUTI) with its…
AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition
In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics,…
Schrödinger stock skyrockets as Novartis invests billions in new partnership
In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement…
Recursion Pharmaceuticals and Exscientia announce merger to transform drug development
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths…
Owkin and AWS join forces to transform precision medicine
Owkin, a pioneering TechBio company known for combining human and artificial intelligence to tailor treatments for individual patients,…
Owkin and AWS forge path to precision medicine with strategic collaboration
Owkin, a pioneering TechBio company, has announced a strategic collaboration with Amazon Web Services (AWS) to innovate in…
SCIEX launches Echo MS+ System to enhance drug discovery through advanced mass spectrometry
SCIEX, a world-renowned leader in life science analytical technologies, introduced the Echo MS+ system at the Society for…
Absci, PrecisionLife collaborate to develop novel biotherapeutics for chronic diseases
Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife, a leader in computational biology, today announced…